Pharma Pulse: Long COVID Exercise Win, $150M Gene Editing Play, and Compounding Pharmacy Expansions

Dec 03, 01:56 PM

Headliner
Share
Subscribe
In today’s Pharma Pulse, a structured exercise program is proven to manage persistent long COVID symptoms, while Regeneron commits $150 million upfront to Tessera for a gene writing therapy targeting AATD, and Strive Pharmacy invests in a massive Arizona facility to boost national personalized medicine capacity.
Share
Subscribe
Next
Pharma Pulse: Pazdur Retires from FDA, While Public Trusts AMA Over CDC on Vaccines, and New Data Redefines Adherence as an Emotional Crisis
Top episodes
Incorporating AI into Commercialization Plans
by Pharmaceutical Commerce
Overcoming Supply Chain Challenges
by Pharmaceutical Commerce
The Capabilities of a 3PL Provider
by Pharmaceutical Commerce